Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy
David Gyori, … , Len R. Stephens, Phillip T. Hawkins
David Gyori, … , Len R. Stephens, Phillip T. Hawkins
Published June 7, 2018
Citation Information: JCI Insight. 2018;3(11):e120631. https://doi.org/10.1172/jci.insight.120631.
View: Text | PDF
Research Article Immunology Oncology

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

  • Text
  • PDF
Abstract

Redundancy and compensation provide robustness to biological systems but may contribute to therapy resistance. Both tumor-associated macrophages (TAMs) and Foxp3+ regulatory T (Treg) cells promote tumor progression by limiting antitumor immunity. Here we show that genetic ablation of CSF1 in colorectal cancer cells reduces the influx of immunosuppressive CSF1R+ TAMs within tumors. This reduction in CSF1-dependent TAMs resulted in increased CD8+ T cell attack on tumors, but its effect on tumor growth was limited by a compensatory increase in Foxp3+ Treg cells. Similarly, disruption of Treg cell activity through their experimental ablation produced moderate effects on tumor growth and was associated with elevated numbers of CSF1R+ TAMs. Importantly, codepletion of CSF1R+ TAMs and Foxp3+ Treg cells resulted in an increased influx of CD8+ T cells, augmentation of their function, and a synergistic reduction in tumor growth. Further, inhibition of Treg cell activity either through systemic pharmacological blockade of PI3Kδ, or its genetic inactivation within Foxp3+ Treg cells, sensitized previously unresponsive solid tumors to CSF1R+ TAM depletion and enhanced the effect of CSF1R blockade. These findings identify CSF1R+ TAMs and PI3Kδ-driven Foxp3+ Treg cells as the dominant compensatory cellular components of the immunosuppressive tumor microenvironment, with implications for the design of combinatorial immunotherapies.

Authors

David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 Total
Citations: 8 11 16 18 13 9 5 1 81
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (81)

Title and authors Publication Year
Ad-SGE-DKK3 gene therapy against resistance to immune checkpoint blockade in malignant mesothelioma
Hee-Jin Jang, Meera Patel, Daniel Y Wang, Sung Kang, Jong Choi, Monica Vilchis, Claire Lee, Ji Seon Shim, Priyanka Ranchod, Sonali Mitra, Allen Kuncheria, William Hudson, Peter Jindra, Veronica Rosen, Maheshwari Ramineni, Ernest Camp, Farrah Kheradmand, R. Ripley, Shawn Groth, Hyun-Sung Lee, Bryan Burt
Clinical cancer research : an official journal of the American Association for Cancer Research 2025
Mitochondrial DNA lineages determine tumor progression through T cell reactive oxygen signaling
Yardeni T, Olali AZ, Chen HW, Wang L, Halton JA, Zenab A, Morrow R, Butic A, Murdock DG, Waymire KG, MacGregor GR, Boursi B, Beier UH, Hancock WW, Wallace DC
Proceedings of the National Academy of Sciences of the United States of America 2025
Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation
Huang T, Wei L, Zhou H, Liu J
Cancer Medicine 2025
Myeloid cells: key players in tumor microenvironments.
Hua Q, Li Z, Weng Y, Wu Y, Zheng L
Frontiers of medicine 2025
Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy.
Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L
Journal of experimental & clinical cancer research : CR 2025
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives
Fu R, Hu R, Li W, Lv X, Zhao H, Li F
Frontiers in Immunology 2025
Macrophages in prostate cancer: dual roles in tumor progression and immune evasion
Liu R, Lu J, Liu J, Liao Y, Guo Y, Shi P, Wang Z, Wang H, Lai J
Journal of Translational Medicine 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
Rosenbaum E, Seier K, Bradic M, Movva S, Kelly CM, Dickson MA, Keohan ML, Gounder MM, Chi P, Nacev BA, Chan JE, Avutu V, Biniakewitz M, Jasnani S, Duchemin M, Desir R, Wong P, Erinjeri J, Hwang S, Antonescu CR, Qin LX, Tap WD, D\u2019Angelo SP
ESMO Open 2025
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
Sharma N, Fan X, Atolagbe OT, Ge Z, Dao KN, Sharma P, Allison JP
Journal of Experimental Medicine 2024
De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis
Sandor LF, Huh JB, Benko P, Hiraga T, Poliska S, Dobo-Nagy C, Simpson JP, Homer NZ, Mahata B, Gyori DS
Cell Reports 2024
The ins and outs of microglial cells in brain health and disease
Pallarés-Moratalla C, Bergers G
Frontiers in immunology 2024
Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip
Suryavanshi P, Bodas D
Nanotheranostics 2024
Defining mesenchymal stem/stromal cell-induced myeloid-derived suppressor cells using single-cell transcriptomics
Lee HJ, Choi YR, Ko JH, Ryu JS, Oh JY
Molecular Therapy 2024
The genomic landscape of the immune system in lung cancer: present insights and continuing investigations
Roshan-Zamir M, Khademolhosseini A, Rajalingam K, Ghaderi A, Rajalingam R
Frontiers in Genetics 2024
The protective role of GATA6+ pericardial macrophages in pericardial inflammation
Hughes DM, Won T, Talor MV, Kalinoski HM, Jurčová I, Szárszoi O, Stříž I, Čurnová L, Bracamonte-Baran W, Melenovský V, Čiháková D
iScience 2024
Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells
Zou D, Xin X, Xu Y, Xu H, Huang L, Xu T
Heliyon 2024
CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker
Zhu Z, Liu H, Fu H, Luo Y, Chen B, Wu X, Sun A, Zhang F, Wang T
Scientific Reports 2024
CSF1 mediating 3-hydroxyhexanoate in endometrial cancer: a Mendelian randomization study
Jiazhen H, Bozhen F
Archives of Medical Science : AMS 2024
Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer
Wang X, Yin X, Li Y, Zhang S, Hu M, Wei M, Li Z
Journal of Nanobiotechnology 2024
Non-invasive imaging of tumor-associated macrophages under anti-PD1 treatment in a murine model of melanoma
Gyo Jeong Gu, Hyewon Chung, Ji Yong Park, Ran Yoo, Hyung Im, Hongyoon Choi, Yun-Sang Lee, Seung Seok
Journal of nanobiotechnology 2023
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
Wang Z, Zhou H, Xu J, Wang J, Niu T
Frontiers in immunology 2023
Interaction of tumor-associated macrophages with stromal and immune components in solid tumors: Research progress (Review)
Kazakova A, Sudarskikh T, Kovalev O, Kzhyshkowska J, Larionova I
International journal of oncology 2023
The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches
Kalluri AL, Shah PP, Lim M
International journal of molecular sciences 2023
Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer
Alshaebi F, Safi M, Algabri YA, Al-Azab M, Aldanakh A, Alradhi M, Reem A, Zhang C
Frontiers in Oncology 2023
Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
Zhang W, Jiang X, Zou Y, Yuan L, Wang X
Frontiers in pharmacology 2023
Therapeutic targeting of tumour myeloid cells.
Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP
Nature reviews. Cancer 2023
Ecological niches for colorectal cancer stem cell survival and thrival
Che J, Yu S
Frontiers in Oncology 2023
Role of tumor-associated macrophages in common digestive system malignant tumors
Shen Y, Chen JX, Li M, Xiang Z, Wu J, Wang YJ
World journal of gastrointestinal oncology 2023
Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies.
Glasner A, Rose SA, Sharma R, Gudjonson H, Chu T, Green JA, Rampersaud S, Valdez IK, Andretta ES, Dhillon BS, Schizas M, Dikiy S, Mendoza A, Hu W, Wang ZM, Chaudhary O, Xu T, Mazutis L, Rizzuto G, Quintanal-Villalonga A, Manoj P, de Stanchina E, Rudin CM, Pe'er D, Rudensky AY
Nature Immunology 2023
Spatiotemporal Characterization of Human Early Intervertebral Disc Formation at Single‐Cell Resolution
Zhou T, Chen Y, Liao Z, Zhang L, Su D, Li Z, Yang X, Ke X, Liu H, Chen Y, Weng R, Shen H, Xu C, Wan Y, Xu R, Su P
Advanced Science 2023
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.
Al-Sudani H, Ni Y, Jones P, Karakilic H, Cui L, Johnson LDS, Rose PG, Olawaiye A, Edwards RP, Uger RA, Lin GHY, Mahdi H
npj Precision Oncology 2023
Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors.
Matos AI, Peres C, Carreira B, Moura LIF, Acúrcio RC, Vogel T, Wegener E, Ribeiro F, Afonso MB, Santos FMF, Martínez-Barriocanal Á, Arango D, Viana AS, Góis PMP, Silva LC, Rodrigues CMP, Graca L, Jordan R, Satchi-Fainaro R, Florindo HF
2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Djureinovic D, Weiss SA, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto AL, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech SM, Bosenberg M, Jilaveanu LB, Kluger HM
Molecular Cancer 2023
Targeting Myeloid-Derived Suppressor Cell Trafficking as a Novel Immunotherapeutic Approach in Microsatellite Stable Colorectal Cancer
Johnson B
Cancers 2023
FOXP3-regulated lncRNA NONHSAT136151 promotes colorectal cancer progression by disrupting QKI interaction with target mRNAs.
Huang H, Liang X, Wu W, Yuan T, Chen Z, Wang L, Wu Z, Zhang T, Yang K, Wen K
Journal of Cellular and Molecular Medicine 2023
CSF1/CSF1R signaling mediates malignant pleural effusion formation
Chrysavgi Kosti, Photene Vaitsi, Apostolos Pappas, Marianthi Iliopoulou, Katherina Psarra, Sophia Magkouta, Ioannis Kalomenidis.
JCI Insight 2022
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
M Prasad, J Zorea, S Jagadeeshan, A Shnerb, S Mathukkada, J Bouaoud, L Michon, O Novoplansky, M Badarni, L Cohen, K Yegodayev, S Tzadok, B Rotblat, L Brezina, A Mock, A Karabajakian, J Fayette, I Cohen, T Cooks, I Allon, O Dimitstein, B Joshua, D Kong, E Voronov, M Scaltriti, Y Carmi, C Conde-Lopez, J Hess, I Kurth, L Morris, P Saintigny, M Elkabets
Journal for ImmunoTherapy of Cancer 2022
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
C Martori, L Sanchez-Moral, T Paul, J Pardo, A Font, V de Porras, M Sarrias
Cancers 2022
Tissue Resident Foxp3+ Regulatory T Cells: Sentinels and Saboteurs in Health and Disease
J Lee, D Kim, B Min
Frontiers in immunology 2022
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
N Kumari, S Choi
Journal of Experimental & Clinical Cancer Research 2022
Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers
D Wu, X Liu, J Mu, J Yang, F Wu, H Zhou
Biomolecules 2022
Role of macrophages in tumor progression and therapy (Review)
Y Xu, X Wang, L Liu, J Wang, J Wu, C Sun
International journal of oncology 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Q Wang, J Bergholz, L Ding, Z Lin, S Kabraji, M Hughes, X He, S Xie, T Jiang, W Wang, J Zoeller, H Kim, T Roberts, P Konstantinopoulos, U Matulonis, D Dillon, E Winer, N Lin, J Zhao
Nature Communications 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A
Journal for ImmunoTherapy of Cancer 2022
Aging Leads to Increased Monocytes and Macrophages With Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma
Duong L, Pixley FJ, Nelson DJ, Jackaman C
2022
Assessment of the TGFB1 gene expression and methylation status of the promoter region in patients with colorectal cancer
Wodziński D, Wosiak A, Pietrzak J, Świechowski R, Kordek R, Balcerczak E
Scientific Reports 2022
CAR T-Cell Targeting of Macrophage Colony-Stimulating Factor Receptor
Achkova DY, Beatson RE, Maher J
Cells 2022
Targeting IL-34/MCSF-1R Axis in Colon Cancer.
Monteleone G, Maresca C, Colella M, Pacifico T, Congiu D, Troncone E, Marafini I
Frontiers in immunology 2022
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies.
Belli C, Antonarelli G, Repetto M, Boscolo Bielo L, Crimini E, Curigliano G
Cancers 2022
Regulatory T Cells in Pancreatic Cancer: Of Mice and Men
Mota Reyes C, Demir E, Çifcibaşı K, Istvanffy R, Friess H, Demir IE
Cancers 2022
Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion.
Lauder SN, Smart K, Bart VMT, Pires A, Scott J, Milutinovic S, Godkin A, Vanhaesebroeck B, Gallimore A
British Journal of Cancer 2022
Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages
Zhu M, Bai L, Liu X, Peng S, Xie Y, Bai H, Yu H, Wang X, Yuan P, Ma R, Lin J, Wu L, Huang M, Li Y, Luo Y
Journal for ImmunoTherapy of Cancer 2022
Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
Chen H, Cresswell GM, Libring S, Ayers MG, Miao J, Zhang ZY, Solorio L, Ratliff TL, Wendt MK
2022
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
J Yeung, V Yaghoobi, D Miyagishima, MD Vesely, T Zhang, T Badri, A Nassar, X Han, MF Sanmamed, M Youngblood, M Peyre, M Kalamarides, DL Rimm, M Gunel, L Chen
Neuro-Oncology 2021
The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)
C Barca, C Foray, S Hermann, U Herrlinger, I Remory, D Laoui, M Schäfers, OM Grauer, B Zinnhardt, AH Jacobs
Frontiers in immunology 2021
Targeting tumor-associated macrophages to synergize tumor immunotherapy
X Xiang, J Wang, D Lu, X Xu
Signal Transduction and Targeted Therapy 2021
Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer
YW Choi, YH Kim, SY Oh, KW Suh, YS Kim, GY Lee, JE Yoon, SS Park, YK Lee, YJ Park, HS Kim, SH Park, JH Kim, TJ Park
Advanced Science 2021
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Y Ni, X Zhou, J Yang, H Shi, H Li, X Zhao, X Ma
Frontiers in Cell and Developmental Biology 2021
PI3K inhibitors are finally coming of age
B Vanhaesebroeck, MW Perry, JR Brown, F André, K Okkenhaug
Nature Reviews Drug Discovery 2021
Immune Therapy Resistance and Immune Escape of Tumors
B Seliger, C Massa
Cancers 2021
Lumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma
Y Zang, Q Dong, Y Lu, K Dong, R Wang, Z Liang
Aging 2021
CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
SF Magkouta, PC Vaitsi, AG Pappas, M Iliopoulou, CN Kosti, K Psarra, IT Kalomenidis
Cancers 2021
Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation
A Piatakova, I Polakova, J Smahelova, SD Johari, J Nunvar, M Smahel
Cancers 2021
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment
SA OBrien, J Orf, KM Skrzypczynska, H Tan, J Kim, J DeVoss, B Belmontes, JG Egen
Cancer Immunology, Immunotherapy 2021
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function
SK Whiteside, FM Grant, DS Gyori, AG Conti, CJ Imianowski, P Kuo, R Nasrallah, F Sadiyah, SA Lira, F Tacke, RL Eil, OT Burton, J Dooley, A Liston, K Okkenhaug, J Yang, R Roychoudhuri
Immunology 2021
TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma
EY Lee, M Kim, BK Choi, DH Kim, I Choi, HJ You
Molecules and Cells 2021
Transcription Factor c-Maf Is A Checkpoint that Programs Macrophages in Lung Cancer
Min Liu, Zan Tong, Chuanlin Ding, Fengling Luo, Shouzhen Wu, Caijun Wu, Sabrin Albeituni, Liqing He, Xiaoling Hu, David Tieri, Eric C. Rouchka, Michito Hamada, Satoru Takahashi, Andrew A. Gibb, Goetz Kloecker, Huang-Ge Zhang, Michael Bousamra, Bradford G. Hill, Xiang Zhang, Jun Yan
Journal of Clinical Investigation 2020
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
N Hama, T Kobayashi, N Han, F Kitagawa, N Kajihara, R Otsuka, H Wada, H Lee, H Rhee, Y Hasegawa, H Yagita, M Baghdadi, K Seino
iScience 2020
Osteoclast Signal Transduction During Bone Metastasis Formation
DS Győri, A Mócsai
Frontiers in Cell and Developmental Biology 2020
CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model
IL Tan, RD Arifa, H Rallapalli, V Kana, Z Lao, RM Sanghrajka, NS Bayin, A Tanne, A Wojcinski, A Korshunov, N Bhardwaj, M Merad, DH Turnbull, JJ Lafaille, AL Joyner
Oncogene 2020
Exosomal MicroRNAs as Mediators of Cellular Interactions Between Cancer Cells and Macrophages
Y Kwon, M Kim, Y Kim, HS Jung, D Jeoung
Frontiers in immunology 2020
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
SN Lauder, K Smart, V Kersemans, D Allen, J Scott, A Pires, S Milutinovic, M Somerville, S Smart, P Kinchesh, E Lopez-Guadamillas, E Hughes, E Jones, M Scurr, A Godkin, LS Friedman, B Vanhaesebroeck, A Gallimore
Journal for ImmunoTherapy of Cancer 2020
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
P Storz, HC Crawford
Gastroenterology 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
AR Razak, JM Cleary, V Moreno, M Boyer, EC Aller, W Edenfield, J Tie, RD Harvey, A Rutten, MA Shah, AJ Olszanski, D Jäger, N Lakhani, DP Ryan, E Rasmussen, G Juan, H Wong, N Soman, MA Smit, D Nagorsen, KP Papadopoulos
Journal for ImmunoTherapy of Cancer 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
KA Autio, CA Klebanoff, D Schaer, JS Kauh, SF Slovin, M Adamow, VS Blinder, M Brahmachary, M Carlsen, E Comen, DC Danila, TN Doman, JC Durack, JJ Fox, JS Gluskin, DM Hoffman, S Kang, P Kang, J Landa, PF McAndrew, S Modi, MJ Morris, R Novosiadly, DE Rathkopf, R Sanford, SC Chapman, CM Tate, D Yu, P Wong, HL McArthur
Clinical cancer research 2020
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
NS Jahchan, AM Mujal, JL Pollack, M Binnewies, V Sriram, L Reyno, MF Krummel
Frontiers in immunology 2019
Blocking inflammation to improve immunotherapy of advanced cancer
A Macciò, C Madeddu
Immunology 2019
PI 3K δ is a Treg target in cancer immunotherapy
EL Lim, K Okkenhaug
Immunology 2019
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
D Hermel, D Sigal
Journal of Personalized Medicine 2019
Macrophage-Mediated Subversion of Anti-Tumour Immunity
V Quaranta, MC Schmid
Cells 2019
Phosphoinositide-3-kinase δ inhibition promotes anti-tumour responses but antagonizes checkpoint inhibitors
Ee Lyn Lim, Fiorella M Cugliandolo, Dalya R Rosner, David Győri, Rahul Roychoudhuri, Klaus Okkenhaug
JCI Insight 2018

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts